Prothena Co. PLC (NASDAQ:PRTA) Expected to Earn FY2019 Earnings of ($2.03) Per Share

Prothena Co. PLC (NASDAQ:PRTA) – Cantor Fitzgerald lifted their FY2019 earnings per share estimates for shares of Prothena in a report issued on Wednesday, November 6th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biotechnology company will post earnings per share of ($2.03) for the year, up from their previous forecast of ($2.14). Cantor Fitzgerald also issued estimates for Prothena’s FY2020 earnings at ($1.34) EPS.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.05. The firm had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.15 million. Prothena had a negative return on equity of 25.54% and a negative net margin of 10,450.00%.

A number of other equities analysts have also issued reports on PRTA. Zacks Investment Research lowered Prothena from a “buy” rating to a “hold” rating and set a $11.00 price target for the company. in a research note on Wednesday, October 23rd. BidaskClub raised Prothena from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 16th. Finally, ValuEngine raised Prothena from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $11.26.

Shares of NASDAQ PRTA opened at $9.07 on Friday. The stock has a fifty day moving average price of $8.28 and a two-hundred day moving average price of $9.13. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.95 and a current ratio of 14.94. The firm has a market cap of $377.42 million, a P/E ratio of -2.51 and a beta of 2.20. Prothena has a 1 year low of $6.71 and a 1 year high of $14.77.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of Prothena by 0.5% during the 2nd quarter. BlackRock Inc. now owns 3,351,908 shares of the biotechnology company’s stock worth $35,431,000 after acquiring an additional 17,619 shares in the last quarter. Orbimed Advisors LLC boosted its stake in shares of Prothena by 25.9% during the 2nd quarter. Orbimed Advisors LLC now owns 3,065,278 shares of the biotechnology company’s stock worth $32,400,000 after acquiring an additional 630,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Prothena by 0.7% during the 2nd quarter. Vanguard Group Inc. now owns 813,376 shares of the biotechnology company’s stock worth $8,597,000 after acquiring an additional 5,817 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Prothena by 7.4% during the 2nd quarter. Northern Trust Corp now owns 520,811 shares of the biotechnology company’s stock worth $5,504,000 after acquiring an additional 35,777 shares in the last quarter. Finally, Nuveen Asset Management LLC bought a new stake in shares of Prothena during the 2nd quarter worth $2,674,000. 96.89% of the stock is owned by institutional investors and hedge funds.

About Prothena

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.

Featured Story: What causes a recession?

Earnings History and Estimates for Prothena (NASDAQ:PRTA)

Leave a Reply

Your email address will not be published. Required fields are marked *

*